Blog

Our know-how

Biomedican - Cannabigerol CBG

What is CBG? Which is better CBD or CBG?

December 16, 2020
Although cannabidiol (CBD) is one of the most popular forms of medical cannabis, research suggests that cannabigerol (CBG), another molecule found in cannabis plants, also offers significant and unique health benefits. What is CBG?  CBG is one of over 120 cannabinoids, which have been discovered within the Cannabis sativa plant ...Read More
Biomedican Astaxanthin

What is Astaxanthin? What is it used for?

December 2, 2020
A rich, red nutrient called Astaxanthin has become increasingly popular due to its myriad of health benefits. Astaxanthin is naturally found within plants and is part of the family of micronutrients known as carotenoids. It is a powerful antioxidant that can support skin, heart, and brain health. What is astaxanthin ...Read More
Biomedican - biosynthetic platform

What is a Biosynthetic Platform?

November 24, 2020
A biosynthetic platform uses the principles of synthetic biology to generate a product. Synthetic biology is defined as “a field of science that involves redesigning organisms for useful purposes by engineering them to have new abilities.” This technique has allowed scientists and engineers to make great advances, including: Modification of ...Read More
Invest in cannabis

Why invest in socially responsible cannabis?

November 12, 2020
Cannabis continues to be one of the fastest-growing industries globally. In the United States alone, 11 states have legalized cannabis completely. 37 other states have legalized it for medical use (with limits on THC content). It is predicted that the global market for cannabinoid-based pharmaceuticals will reach $50 ...Read More
Biomedican - yeast fermentation

Biosynthesis of cannabinoids vs. chemical synthesis

October 12, 2020
What is the biosynthesis of cannabinoids? Biosynthesis is the process in which naturally occurring reagents and catalysts are used to create compounds identical to those found in nature. Biosynthesis of cannabinoids allows their production to be faster, cost-effective, and more sustainable than alternative methods. Biosynthetic cannabinoids grow through naturally ...Read More
Biomedican - yeast

How to grow rare cannabinoids in yeast

September 10, 2020
Cannabinoids are naturally occurring compounds found in the Cannabis sativa plant. As we’ve discussed in one of our previous blogs, these compounds have immense potential for consumer products and unique medicinal benefits. However, as we talked, rare cannabinoids occur naturally in the plant Cannabis sativa, but in extremely small ...Read More
Biomedican - cannabinoids guide

Rare cannabinoids: discover the endless health benefits

August 10, 2020
Which associations pop up in your mind when you hear the word “cannabis”? While many people still think of it as a recreational drug, this perception is not accurate and very limited. Following its legalization, the cannabinoid industry has been garnering a lot of attention in recent years ...Read More

Publications about us

Biomedican on Forbes

Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products – Forbes

November 15, 2020
Forbes contributor, Amanda Siebert, analyzed the rise of rare cannabinoids, including CBG, CBN, and others in her recent article “Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products.” As a part of this article, Max Mikheev and Dennis O’Neil of Biomedican shared our unique ...Read More

Cannabinoids Beyond THC And CBD Pique Market Interest – Benzinga

November 9, 2020
In a recent article “Cannabinoids Beyond THC And CBD Pique Market Interest” published in Benzinga, Andrew Ward brought the less-known cannabinoids into the light. He regarded THC and CBD as “just the tip of a massive iceberg”. Dennis O’Neill, co-founder of Biomedican elaborated the importance of ...Read More
This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to backburner, what employers should know

This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to the backburner, what employers should know

November 4, 2020
An article “ This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to the backburner, what employers should know” recently published by N.J. Cannabis Insider staff explained Biomedican’s approach to biosynthesize cannabinoids. Dennis O’Neill stated biosynthesis as a significant opportunity for Biomedican ...Read More
Biomedican on Bloomberg

Race Is On for Synthetic Cannabinoids – Bloomberg

November 4, 2020
In the recent article, “Race Is On for Synthetic Cannabinoids: Cannabis Weekly” published in Bloomberg, Tiffany Kary highlighted that increased demand and popularity of cannabis resulted in an increased race for production of synthetic rare cannabinoids. Some companies are scaling up efforts to engineer lesser-known cannabinoids such ...Read More
How Rare Cannabinoids are Disrupting the Pharmaceutical Industry

How Rare Cannabinoids are Disrupting the Pharmaceutical Industry-DrugTopics

November 3, 2020
CEO and Founder of BIOMEDICAN, Maxim Mikheev, explained biosynthesis, usage of rare cannabinoids, and their impact on pharmaceuticals in the recent publication “How Rare Cannabinoids Are Disrupting the Pharmaceutical Industry.” In addition to the most well-known cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), the latest research ...Read More
Cannabis companies, betting on a Biden win, ready IPOs

Cannabis companies, betting on a Biden win, ready IPOs – Reuters

October 21, 2020
An article “Cannabis companies, betting on a Biden win, ready IPOs” published in Reuters by Shariq Khan and David Randall highlighted that increased demand for cannabis during Covid-19 caused Cannabis companies to bet on Biden win who aims to decriminalized cannabis at a federal level. Article shared Biomedican’s ...Read More

Is The Cannabis Market Ready For Lab-Grown Cannabinoids? – Benzinga

October 12, 2020
Natan Ponieman in a recent article “Is The Cannabis Market Ready For Lab-Grown Cannabinoids?” shared the importance of Lab-Grown cannabinoids. Maxim Mikheev and Dennis O’Neill of Biomedican narrated our continuous fermentation approach toward the production of cannabinoids. The disruptive ability of plant produced THC and CBD ...Read More
Biomedican on Nasdaq

Why CBG and Other Rare Cannabinoids Will Supplant CBD – Nasdaq

September 28, 2020
In a recent article “Why CBG and Other Rare Cannabinoids Will Supplant CBD” published in Nasdaq, CEO and founder of Biomedican Max Makhieev featured the importance of highly popular rare cannabinoids that can dominate CBD. The cannabis market is projected to reach $146.4 billion by 2025 due to the ...Read More
AXIOS SUMMARY

Startups want to biosynthesize CBD – Axios

September 12, 2020
Axios’s author Bryan Walsh highlighted the importance of Biosynthetically produced cannabinoids over traditionally cultivated cannabinoids. Dennis O’Neill of Biomedican also shared our unique approach -Biosynthesis of Cannabinoids- in the same article “Startups want to biosynthesize CBD”. The rapidly growing cannabis market started a race of various companies ...Read More
Biomedican in Biofuel Digest

Cannabinoids from yeast not plants – Biofuels Digest

September 11, 2020
Helena Tavares Kennedy recently published an article “Plants without the plant? A look at cannabinoids made with yeasts instead of plants” in Biofuels Digest, in which she highlighted Biomedican’s approach towards the production of cannabis without a plant. She explained how yeast-to-cannabinoid proprietary technology came about, who ...Read More